Figure 10.

Therapeutic efficacy of compound 36l in the pancreatic tumor PDX model. When the tumor reached about 100 mm³ (set to day 0), the mice were divided into three group randomly. Then, the groups were respectively treated with the compound 36l (50 mg/kg, QD) intraperitoneally, gemcitabine (30 mg/kg, once every 3 days) and saline intravenously until the endpoint. (A) Effect of 36l on tumor volume growth in PDX models. (B) Effect of 36l on body weight in PDX models. (C) Weight of the PDX tumor treated with vehicle, gemcitabine and 36l. (D) Quantification of Ki-67 positive cells³⁸. (E) Representative images of H&E staining and IHC staining for Ki-67 of tumor tissues treated by vehicle, gemcitabine and 36l. Scale bar: 200 μm. Data were represented as the mean ± standard deviation, n = 5. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.